|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Grégoire V, Lefebvre JL, Licitra L and
Felip E; EHNS-ESMO-ESTRO Guidelines Working Group: Squamous cell
carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
21(Suppl 5): V184–V186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Galbiatti AL, Padovani-Junior JA, Maníglia
JV, Rodrigues CD, Pavarino EC and Goloni-Bertollo EM: Head and neck
cancer: Causes, prevention and treatment. Braz J Otorhinolaryngol.
79:239–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
The Royal College of Radiologists:
Radiotherapy Dose-fractionation. 2006, https://www.rcr.ac.uk/publication/radiotherapy-dose-fractionation.
Accessed December, 2013.
|
|
5
|
Burtness B: Moving forward in the
management of squamous cell carcinoma of the head and neck:
Promising immuno-oncology approaches. Am J Hematol Oncol. 11:28–31.
2015.
|
|
6
|
Sadraei NH, Sikora AG and Brizel DM:
Immunotherapy and checkpoint inhibitors in recurrent and metastatic
head and neck cancer. Am Soc Clin Oncol Educ Book. 35:e277–282.
2016. View Article : Google Scholar
|
|
7
|
Head and Neck NSSG; Head and Neck Network
Group: Head and Neck Cancer Treatment Guidelines. NHS; UK: 2014
|
|
8
|
American Cancer Society: Cancer Facts and
Figures 2015. American Cancer Society Inc; Atlanta, GA: 2015
|
|
9
|
Scaife L, Hodgkinson VC, Drew PJ, Lind MJ
and Cawkwell L: Differential proteomics in the search for
biomarkers of radiotherapy resistance. Expert Rev Proteomics.
8:535–552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Biau J, Chautard E, Miroir J and Lapeyre
M: Radioresistance parameters in head and neck cancers and methods
to radiosensitize. Cancer Radiother. 19:337–346. 2015. View Article : Google Scholar
|
|
11
|
Guy JB, Rancoule C, Méry B, Espenel S,
Wozny AS, Simonet S, Vallard A, Alphonse G, Ardail D,
Rodriguez-Lafrasse C, et al: Radiosensitivity and/or
radioresistance of head and neck cancers: Biological angle. Bull
Cancer. 103:41–47. 2016.In French. View Article : Google Scholar
|
|
12
|
Ataman OU, Bentzen SM, Wilson GD, Daley
FM, Richman PI, Saunders MI and Dische S: Molecular biomarkers and
site of first recurrence after radiotherapy for head and neck
cancer. Eur J Cancer. 40:2734–2741. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kumar B, Cordell KG, Lee JS, Worden FP,
Prince ME, Tran HH, Wolf GT, Urba SG, Chepeha DB, Teknos TN, et al:
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as
indicators of response to therapy and survival in oropharyngeal
cancer. J Clin Oncol. 26:3128–3137. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moeller BJ, Yordy JS, Williams MD, Giri U,
Raju U, Molkentine DP, Byers LA, Heymach JV, Story MD, Lee JJ, et
al: DNA repair biomarker profiling of head and neck cancer: Ku80
expression predicts locoregional failure and death following
radiotherapy. Clin Cancer Res. 17:2035–2043. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Akervall J, Nandalur S, Zhang J, Qian CN,
Goldstein N, Gyllerup P, Gardinger Y, Alm J, Lorenc K, Nilsson K,
et al: A novel panel of biomarkers predicts radioresistance in
patients with squamous cell carcinoma of the head and neck. Eur J
Cancer. 50:570–581. 2014. View Article : Google Scholar
|
|
16
|
Kilic S, Cracchiolo B, Gabel M, Haffty B
and Mahmoud O: The relevance of molecular biomarkers in cervical
cancer patients treated with radiotherapy. Ann Transl Med.
3:2612015.PubMed/NCBI
|
|
17
|
Sharma A, Bode B, Wenger RH, Lehmann K,
Sartori AA, Moch H, Knuth A, Boehmer L and Broek M: γ-Radiation
promotes immunological recognition of cancer cells through
increased expression of cancer-testis antigens in vitro and in
vivo. PLoS One. 6:e282172011. View Article : Google Scholar
|
|
18
|
Carr SD, Green VL, Stafford ND and
Greenman J: Analysis of radiation-induced cell death in head and
neck squamous cell carcinoma and rat liver maintained in
microfluidic devices. Otolaryngol Head Neck Surg. 150:73–80. 2014.
View Article : Google Scholar
|
|
19
|
Ma H, Xu H and Qin J: Biomimetic tumor
microenvironment on a microfluidic platform. Biomicrofluidics.
7:115012013. View Article : Google Scholar
|
|
20
|
Halldorsson S, Lucumi E, Gómez-Sjöberg R
and Fleming RM: Advantages and challenges of microfluidic cell
culture in polydimethylsiloxane devices. Biosens Bioelectron.
63:218–231. 2015. View Article : Google Scholar
|
|
21
|
van der Meer AD and van den Berg A:
Organs-on-chips: Breaking the in vitro impasse. Integr Biol.
4:461–470. 2012. View Article : Google Scholar
|
|
22
|
Hattersley SM, Sylvester DC, Dyer CE,
Stafford ND, Haswell SJ and Greenman J: A microfluidic system for
testing the responses of head and neck squamous cell carcinoma
tissue biopsies to treatment with chemotherapy drugs. Ann Biomed
Eng. 40:1277–1288. 2012. View Article : Google Scholar
|
|
23
|
Hattersley SM, Dyer CE, Greenman J and
Haswell SJ: Development of a microfluidic device for the
maintenance and interrogation of viable tissue biopsies. Lab Chip.
8:1842–1846. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheah LT, Dou YH, Seymour AM, Dyer CE,
Haswell SJ, Wadhawan JD and Greenman J: Microfluidic perfusion
system for maintaining viable heart tissue with real-time
electrochemical monitoring of reactive oxygen species. Lab Chip.
10:2720–2726. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hakem R: DNA-damage repair; the good, the
bad, and the ugly. EMBO J. 27:589–605. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mahaney BL, Meek K and Lees-Miller SP:
Repair of ionizing radiation-induced DNA double-strand breaks by
non-homologous end-joining. Biochem J. 417:639–650. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Willers H, Azzoli CG, Santivasi WL and Xia
F: Basic mechanisms of therapeutic resistance to radiation and
chemotherapy in lung cancer. Cancer J. 19:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Olive PL and Banáth JP: Kinetics of H2AX
phosphorylation after exposure to cisplatin. Cytometry B Clin
Cytom. 76:79–90. 2009. View Article : Google Scholar
|
|
29
|
Taneja N, Davis M, Choy JS, Beckett MA,
Singh R, Kron SJ and Weichselbaum RR: Histone H2AX phosphorylation
as a predictor of radiosensitivity and target for radiotherapy. J
Biol Chem. 279:2273–2280. 2004. View Article : Google Scholar
|
|
30
|
McCreedy T and Wilson NG: Microfabricated
reactors for on-chip heterogeneous catalysis. Analyst (Lond).
126:21–23. 2001. View
Article : Google Scholar
|
|
31
|
Astolfi M, Péant B, Lateef MA, Rousset N,
Kendall-Dupont J, Carmona E, Monet F, Saad F, Provencher D,
Mes-Masson AM, et al: Micro-dissected tumor tissues on chip: An ex
vivo method for drug testing and personalized therapy. Lab Chip.
16:312–325. 2016. View Article : Google Scholar
|
|
32
|
Loo DT: TUNEL assay. An overview of
techniques. Methods Mol Biol. 203:21–30. 2002.PubMed/NCBI
|
|
33
|
Richmond A and Su Y: Mouse xenograft
models vs GEM models for human cancer therapeutics. Dis Model Mech.
1:78–82. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stein AP, Swick AD, Smith MA, Blitzer GC,
Yang RZ, Saha S, Harari PM, Lambert PF, Liu CZ and Kimple RJ:
Xenograft assessment of predictive biomarkers for standard head and
neck cancer therapies. Cancer Med. 4:699–712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang J, Liu A, Dougherty C, Chen X, Guzman
R and Nandi S: Beware of contaminating mouse cells in human
xenografts from nude mice. Anticancer Res. 20A:1635–1639. 2000.
|
|
36
|
Garrido-Laguna I, Uson M, Rajeshkumar NV,
Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor
G, Sharma R, et al: Tumor engraftment in nude mice and enrichment
in stroma- related gene pathways predict poor survival and
resistance to gemcitabine in patients with pancreatic cancer. Clin
Cancer Res. 17:5793–5800. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kahn J, Tofilon PJ and Camphausen K:
Preclinical models in radiation oncology. Radiat Oncol. 7:2232012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kimple RJ, Harari PM, Torres AD, Yang RZ,
Soriano BJ, Yu M, Armstrong EA, Blitzer GC, Smith MA, Lorenz LD, et
al: Development and characterization of HPV-positive and
HPV-negative head and neck squamous cell carcinoma tumor-grafts.
Clin Cancer Res. 19:855–864. 2013. View Article : Google Scholar
|
|
39
|
Malaney P, Nicosia SV and Davé V: One
mouse, one patient paradigm: New avatars of personalized cancer
therapy. Cancer Lett. 344:1–12. 2014. View Article : Google Scholar :
|
|
40
|
Stebbing J, Paz K, Schwartz GK, Wexler LH,
Maki R, Pollock RE, Morris R, Cohen R, Shankar A, Blackman G, et
al: Patient-derived xenografts for individualized care in advanced
sarcoma. Cancer. 120:2006–2015. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dawson AL, Green VL, Bower R and Greenman
J: Microfluidics: The fur-free way towards personalised medicine in
cancer therapy. Univ Hull. 3:12–17. 2016.
|
|
42
|
Zhou GQ, Ren XY, Mao YP, Chen L, Sun Y,
Liu LZ, Li L, Lin AH, Mai HQ and Ma J: Prognostic implications of
dynamic serum lactate dehydrogenase assessments in nasopharyngeal
carcinoma patients treated with intensity-modulated radiotherapy.
Sci Rep. 6:223262016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Raybaud H, Fortin A, Bairati I, Morency R,
Monteil RA and Têtu B: Nuclear DNA content, an adjunct to p53 and
Ki-67 as a marker of resistance to radiation therapy in oral cavity
and pharyngeal squamous cell carcinoma. Int J Oral Maxillofac Surg.
29:36–41. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sundquist T, Moravec R, Niles A, O'Brien M
and Riss T: Timing your apoptosis assays. Cell Notes. 16:18–21.
2006.
|
|
45
|
Feng J, Zou J, Li L, Zhao Y and Liu S:
Antisense oligodeoxy-nucleotides targeting ATM strengthen apoptosis
of laryngeal squamous cell carcinoma grown in nude mice. J Exp Clin
Cancer Res. 30:432011. View Article : Google Scholar
|
|
46
|
Zou J, Qiao X, Ye H, Yang Y, Zheng X, Zhao
H and Liu S: Antisense inhibition of ATM gene enhances the
radiosensitivity of head and neck squamous cell carcinoma in mice.
J Exp Clin Cancer Res. 27:562008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Valdiglesias V, Giunta S, Fenech M, Neri M
and Bonassi S: γH2AX as a marker of DNA double-strand breaks and
genomic instability in human population studies. Mutat Res.
753:24–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Banáth JP, Macphail SH and Olive PL:
Radiation sensitivity, H2AX phosphorylation, and kinetics of repair
of DNA strand breaks in irradiated cervical cancer cell lines.
Cancer Res. 64:7144–7149. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Clingen PH, Wu JY, Miller J, Mistry N,
Chin F, Wynne P, Prise KM and Hartley JA: Histone H2AX
phosphorylation as a molecular pharmacological marker for DNA
interstrand crosslink cancer chemotherapy. Biochem Pharmacol.
76:19–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Debucquoy A, Goethals L, Libbrecht L,
Perneel C, Geboes K, Ectors N, McBride WH and Haustermans K:
Molecular and clinico-pathological markers in rectal cancer: A
tissue microarray study. Int J Colorectal Dis. 24:129–138. 2009.
View Article : Google Scholar
|
|
51
|
Debucquoy A, Libbrecht L, Roobrouck V,
Goethals L, McBride W and Haustermans K: Morphological features and
molecular markers in rectal cancer from 95 patients included in the
European Organisation for Research and Treatment of Cancer 22921
trial: Prognostic value and effects of preoperative radio (chemo)
therapy. Eur J Cancer. 44:791–797. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fareed KR, Soomro IN, Hameed K, Arora A,
Lobo DN, Parsons SL and Madhusudan S: Caspase-cleaved
cytokeratin-18 and tumour regression in gastro-oesophageal
adenocarcinomas treated with neoadjuvant chemotherapy. World J
Gastroenterol. 18:1915–1920. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Koukourakis MI: Radiation damage and
radioprotectants: New concepts in the era of molecular medicine. Br
J Radiol. 85:313–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Buffa FM, Bentzen SM, Daley FM, Dische S,
Saunders MI, Richman PI and Wilson GD: Molecular marker profiles
predict locoregional control of head and neck squamous cell
carcinoma in a randomized trial of continuous hyperfractionated
accelerated radiotherapy. Clin Cancer Res. 10:3745–3754. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kee N, Sivalingam S, Boonstra R and
Wojtowicz JM: The utility of Ki-67 and BrdU as proliferative
markers of adult neurogenesis. J Neurosci Methods. 115:97–105.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Turesson I, Bernefors R, Book M, Flogegård
M, Hermansson I, Johansson KA, Lindh A, Sigurdardottir S, Thunberg
U and Nyman J: Normal tissue response to low doses of radiotherapy
assessed by molecular markers - a study of skin in patients treated
for prostate cancer. Acta Oncol. 40:941–951. 2001. View Article : Google Scholar
|
